Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what plans (a) NICE and (b) NHS England has to issue a consultation on changes to the highly specialised technologies evaluation programme.
Answered by Baroness Blackwood of North Oxford
The National Institute for Health and Care Excellence and NHS England launched a joint consultation on 13 October 2016 setting out proposed changes to the arrangements for the evaluation and adoption of new technologies, including on the methodology for the evaluation of highly specialised technologies.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, whether he plans to appeal NICE's draft guidance on asfotase alfa for treating paediatric-onset hypophosphatasia, issued in September 2016.
Answered by Baroness Blackwood of North Oxford
The National Institute for Health and Care Excellence (NICE) is currently evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.
There has not yet been an opportunity for stakeholders to appeal NICE’s recommendations on the use of asfotase alfa for treating paediatric-onset hypophosphatasia. NICE published a second iteration of draft guidance for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation before deciding on the next steps for the evaluation.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps his Department is taking to ensure that asfotase alfa is available on the NHS to all patients who may benefit from it.
Answered by Baroness Blackwood of North Oxford
The National Institute for Health and Care Excellence (NICE) is currently evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.
There has not yet been an opportunity for stakeholders to appeal NICE’s recommendations on the use of asfotase alfa for treating paediatric-onset hypophosphatasia. NICE published a second iteration of draft guidance for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation before deciding on the next steps for the evaluation.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if he will make an assessment of the potential effect of implementing the recommendations contained in NICE's evaluation consultation document, Asfotase alfa for treating paediatric-onset hypophosphatasia, published on 22 September 2016, on the outcomes of people living with that disease.
Answered by Baroness Blackwood of North Oxford
The National Institute for Health and Care Excellence (NICE) is an independent body and is evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.
NICE published its draft recommendations for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation. NICE has not yet issued its final guidance on this treatment and its draft recommendations may change following consultation.